scholarly journals Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group

Radiology ◽  
2017 ◽  
Vol 285 (2) ◽  
pp. 482-492 ◽  
Author(s):  
Hebert Alberto Vargas ◽  
Erich P. Huang ◽  
Yulia Lakhman ◽  
Joseph E. Ippolito ◽  
Priya Bhosale ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Research Group ◽  
Cancer Imaging ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Imaging Research ◽  
Cancer Genome Atlas ◽  
Genome Atlas

Clinical translation of the cancer genome atlas signature for ovarian cancer survival

2012 ◽  
Vol 125 ◽  
pp. S42
Author(s):  
G. Sfakianos ◽  
E. Iversen ◽  
W. Lowery ◽  
R. Whitaker ◽  
L. Akushevich ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Cancer Genome ◽  
Clinical Translation ◽  
The Cancer Genome Atlas ◽  
Cancer Genome Atlas ◽  
Ovarian Cancer Survival ◽  
Genome Atlas

scholarly journals TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas

2015 ◽  
Vol 138 (1) ◽  
pp. 159-164 ◽  
Author(s):  
Brandon-Luke L. Seagle ◽  
Chia-Ping Huang Yang ◽  
Kevin H. Eng ◽  
Monica Dandapani ◽  
Oluwatosin Odunsi-Akanji ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hot Spot ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Survival Outcomes ◽  
Differential Survival ◽  
Cancer Genome Atlas ◽  
Genome Atlas

scholarly journals Prognostic values of GMPS, PR, CD40, and p21 in ovarian cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6301 ◽  
Author(s):  
Ping Wang ◽  
Zengli Zhang ◽  
Yujie Ma ◽  
Jun Lu ◽  
Hu Zhao ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Differential Expression ◽  
Cancer Progression ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Progression Model ◽  
Cancer Genome Atlas ◽  
Genome Atlas

Early detection and prediction of prognosis and treatment responses are all the keys in improving survival of ovarian cancer patients. This study profiled an ovarian cancer progression model to identify prognostic biomarkers for ovarian cancer patients. Mouse ovarian surface epithelial cells (MOSECs) can undergo spontaneous malignant transformation in vitro cell culture. These were used as a model of ovarian cancer progression for alterations in gene expression and signaling detected using the Illumina HiSeq2000 Next-Generation Sequencing platform and bioinformatical analyses. The differential expression of four selected genes was identified using the gene expression profiling interaction analysis (http://gepia.cancer-pku.cn/) and then associated with survival in ovarian cancer patients using the Cancer Genome Atlas dataset and the online Kaplan–Meier Plotter (http://www.kmplot.com) data. The data showed 263 aberrantly expressed genes, including 182 up-regulated and 81 down-regulated genes between the early and late stages of tumor progression in MOSECs. The bioinformatic data revealed four genes (i.e., guanosine 5′-monophosphate synthase (GMPS), progesterone receptor (PR), CD40, and p21 (cyclin-dependent kinase inhibitor 1A)) to play an important role in ovarian cancer progression. Furthermore, the Cancer Genome Atlas dataset validated the differential expression of these four genes, which were associated with prognosis in ovarian cancer patients. In conclusion, this study profiled differentially expressed genes using the ovarian cancer progression model and identified four (i.e., GMPS, PR, CD40, and p21) as prognostic markers for ovarian cancer patients. Future studies of prospective patients could further verify the clinical usefulness of this four-gene signature.

scholarly journals Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked

2018 ◽  
pp. 1-11
Author(s):  
Amin H. Nassar ◽  
Kevin Lundgren ◽  
Mark Pomerantz ◽  
Eliezer Van Allen ◽  
Lauren Harshman ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pooled Analysis ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
High Grade ◽  
Data Set ◽  
Dana Farber Cancer Institute ◽  
Cancer Genome Atlas ◽  
Never Smokers ◽  
Genome Atlas

Purpose FGFR3-TACC3 (fibroblast growth factor receptor 3–transforming acidic coiled coil-containing protein 3) fusions have recently been identified as driver mutations that lead to the activation of FGFR3 in bladder cancer and other tumor types and are associated with sensitivity to tyrosine kinase inhibitors. We examined the clinical and molecular characteristics of patients with FGFR3-TACC3 fusions and hypothesized that they are enriched in a subset of patients with bladder cancer. Materials and Methods We correlated somatic FGFR3-TACC3 fusions with clinical and molecular features in two cohorts of patients with bladder cancer. The first cohort consisted of the muscle-invasive bladder cancer (MIBC) data set (n = 412) from The Cancer Genome Atlas. The second cohort consisted of patients with MIBC or high-grade non-MIBC at the Dana-Farber Cancer Institute that had targeted capture sequencing of a selected panel of cancer genes (n = 356). All statistical tests were two sided. The clinical response of one patient with FGFR3-TACC3 bladder cancer to an FGFR3 inhibitor was investigated. Results Overall, 751 patients with high-grade bladder cancer without FGFR3-TACC3 fusions and 17 with FGFR3-TACC3 fusions were identified in the pooled analysis of the data sets from The Cancer Genome Atlas and the Dana-Farber Cancer Institute. FGFR3-TACC3 fusions were enriched in patients age ≤ 50 years versus age 51 to 65 years versus those older than 65 years (pooled, P = .002), and were observed in four (12%) of 33 patients age ≤ 50 years in the pooled analysis. Similarly, FGFR3-TACC3 fusions were significantly more common in Asians (13%) compared with African Americans (4%) and whites (2%; pooled, P < .001), as well as in never smokers (5.6%) compared with ever smokers (1.1%; pooled, P < .001). One patient with the fusion who was treated with an FGFR3 inhibitor achieved complete remission for 10 months. Conclusion Clinical testing to identify FGFR3 fusions should be prioritized for patients with bladder cancer who are younger, never smokers, and/or Asian.

Sign in / Sign up

Export Citation Format

Share Document